Overview

Funding Portfolio

$60M+ research funding for adaptive clinical trials, cancer genomics, and precision oncology from ARPA-H, NCI, DOD, and other federal agencies

Scroll for active awards, flagship roles, and embedded cores powering adaptive oncology analytics.

  • Leadership across ARPA-H ADAPT, TBCRC, SPORE, and Lineberger P30
  • PI / Co-PI roles spanning adaptive trials, AI navigation, and core science
  • At-a-glance budget, effort, and period for each flagship grant

Active Funding

$60M+ Active portfolio powering adaptive oncology analytics
6 PI / Co-PI / Core leadership roles
4 Federal agencies (ARPA-H, NCI, DOD, P30)

Flagship Awards

TBCRC EVOLVE_BDT Platform Trial (ARPA-H)

Active
Total $28,120,143
Period 05/2025–05/2028
Role Co-PI / Statistical Lead (1.8 CM)

Adaptive metastasis platform integrating serial tissue, ctDNA, imaging, and machine-learning allocation strategies to reinvent metastatic breast cancer trials.

TrialMatch LLM for Pancreatic Cancer (DOD PCARP)

Active
Total $311,000
Period 11/2024–10/2026
Role Principal Investigator (1.08 CM)

Fine-tuned large language model that translates pancreatic trial eligibility into bilingual patient summaries, reducing disparities in navigation.

Tumor–Stroma Integration U01 (NCI)

Active

Co-PI with Jen Jen Yeh to map tumor–stroma responses across organoids, mixtures, and tissues and link phenotypes to therapeutic vulnerabilities.

See additional PI / Core leadership awards

UNC Breast Cancer SPORE – Core B

Active

Core B co-lead with Katie Hoadley (P50-CA058223, 2024–2029) delivering disparities-aware analytics, biomarker development, and resistance monitoring.

UNC Pancreatic Cancer SPORE – Core C (IQS)

Active

Core C co-lead with Michael Kosorok (P50-CA257911, 2022–2027) building integrated quantitative science pipelines for PDAC translational studies.

UNC Lineberger P30 Biostatistics Shared Resource

Active

Associate Director (P30-CA016086) overseeing design and analytics support for 40+ Lineberger collaborations annually.

See Co-Investigator & Biostatistician portfolio

Cancer Genomics & Precision Medicine

HCMA metabolomics R01, male breast endocrine therapy response, BCRF HER2 programs, and UNC SPORE translational pilots.

Pancreatic Cancer & Immuno-oncology

Four PDAC SPORE projects covering immunosuppression, organoid vulnerabilities, neoantigen therapies, and microenvironment remodeling.

Other Programs

Lineberger shared-resource consults, adaptive trial working groups, and multi-institutional analytics collaborations.